FDA clears Prelude Therapeutics' breast cancer drug trial
核心洞察
Prelude Therapeutics has received FDA clearance of an Investigational New Drug application for PRT13722 (搜索), a first-in-class oral KAT6A (搜索) inhibitor, according to MarketBeat.
The clearance allows the company to begin a Phase 1 trial in hormone receptor-positive, HER2-negative breast cancer (搜索), the program's initial clinical stage.
PRT13722 (搜索) targets KAT6A (搜索), an epigenetic regulator implicated in cancer cell growth, a mechanism not yet validated in the clinic.
Prelude Therapeutics has received U.S. Food and Drug Administration (搜索) clearance of an Investigational New Drug application for PRT13722 (搜索), a first-in-class oral KAT6A (搜索) inhibitor being developed for hormone receptor-positive, HER2-negative breast cancer (搜索), according to MarketBeat. The clearance allows the company to initiate a Phase 1 clinical trial in patients.
PRT13722 (搜索) targets KAT6A (搜索), an epigenetic regulator implicated in cancer cell growth. First-in-class status means Prelude is pursuing a mechanism not yet validated in the clinic, which increases uncertainty around early data. Beyond PRT13722, the company is working on a broader pipeline of small-molecule targeted cancer therapies.
The start of a Phase 1 study following IND clearance is typically the point at which safety and initial signals of activity begin to emerge, making subsequent readouts an important factor for the program. Prelude Therapeutics is active in the biotechnology segment of the healthcare sector.
Source: ad-hoc-news.de